Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sonrotoclax + zanubrutinib versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia
MOH_2024-03-14_013315Phase 3Recruiting
- Sponsor
- BeiGene
- Start
- Mar 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Sonrotoclax + zanubrutinib with Venetoclax + obinutuzumab (2 arms). Primary endpoint: Progression-free survival. Started Mar 2024; status: recruiting.
02
Drugs
sonrotoclaxzanubrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2024-03-14_013315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-14_013315.